American Home Products Corporation

Onconova Therapeutics, Inc.

Basf Aktiengesellschaft

Temple University

Allelix Neuroscience Inc.

Ortho Pharmaceutical Corporation

Alteon Incorporated

Other

John Wyeth Brother, Limited

Synvista Therapeutics, Inc.

Stanley Charles Bell

M V Ramana Reddy

E Premkumar Reddy

Michael P Wachter

Bernd Janssen

William V Murray

Edmond Joseph LaVoie

Dilip R Wagle

Hans-Heiner Wuest

Peter H Wei

Martin Gall

Robert Falotico

Victor T Bandurco

Dieter H Klaubert

Jing Zhang

Alfonso J Tobia

Laurence A Borden

Allen Hopper

Vassil Iliya Ognyanov

Vassil Ilya Ognyanov

Charles F Schwender

Arthur Attilio Santilli

Anthony C Scotese

Donald W Combs

John J Egan

Dong H Kim

Manoj Maniar

Sara Vasan

Michael De Vivo

Mv Ramana Reddy

Methvin Isaac

Eric A Meade

Premkumar E Reddy

Ramana M Reddy

Alan C White

Roland K Robins

Robert H Chen

Richard A Schumacher

Anthony F Kreft, Iii

Ronald J McCaully

John H Dodd

Robert L Morris

William O Weigle

Michael C Goodman

Richard W Rees

William J Hennen

Abraham Nudelman

Marvin E Rosenthale

Thomas W Pattison

Stephen Cosenza

Glenn J Fegley

Jodie Duke

Kathleen Da Silva

Abdelmalik Slassi

Hans H Wuest

Reddy E Premkumar

Reddy M V Ramana

Albert Wong

Anne O'Brien

Ramana M V Reddy

Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of a compound of formula I  and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.

Formulations for parenteral administration of amino-substituted (E)-2, 6-dialkoxystyryl 4-substituted benzylsulfones

Methods of treating cancer using compounds according to Formula (I) are disclosed herein, wherein X, X, X, R, R, R, R, R, R, R, R, g, M, y, a, b, d, e, V, W, Z and Q are as defined herein.

Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones

Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions.

Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions

&#x3b1;,&#x3b2;-Unsaturated sulfides, sulfones, sulfoxides and sulfonamides according to Formula I: wherein Ar, Ar, X, n, * and R are as defined herein, are prepared by dehydration of &#x3b2;-hydroxy sulfides, sulfones, sulfoxides or sulfonamides.

Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis

Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of compound of formula I or a compound of formula IIa and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.

Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones

Substituted phenol derivatives of Formula (I) are useful as antiproliferative agents including, for example, anticancer agents, and as radioprotective and chemoprotective agents.

Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders

&#x3b1;&#x3b2;-Unsaturated sulfoxides of Formula I: 

Alpha, beta-unsaturated sulfoxides for treating proliferative disorders

Compounds useful as antiproliferative agents, including, for example, anticancer agents, are provided according to formula (I); wherein: X, X, X, R, R, R,R, R, R, R, R, g, M, y, a, b, d, e, V, W, Z and Q are as defined herein.

[object Object]

Provided is a method of treating or ameliorating or preventing glaucoma, decreasing intraocular pressure or improving or amemliorting ocular accommodation in an animal, including a human comprising administering an intraocular pressure decreasing or accommodation improving amount of a compound of the formula I: 

Method for treating glaucoma IC

Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 

Method for treating fibrotic diseases and other indications

Compounds useful as antiproliferative agents, including, for example, anticancer agents, are provided according to formula I: wherein: Ar, X, X, g, R and Rare as defined herein.

Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders

Provided are compounds, processes and synthetic intermediates useful for the preparation of compounds of the formula I and IX wherein Ris selected from the group consisting of hydrogen, trihalomethyl, C&#x2013;Calkyl and substituted or unsubstituted phenyl; Y is a group of the formula wherein Ris selected from the group consisting of C&#x2013;Calkyl, C&#x2013;Calkanoylamino and amino; and Ris selected from the group consisting of hydrogen, amino, halogen, hydroxyl, nitro, C&#x2013;Calkyl, C&#x2013;Calkoxy, carboxy, C&#x2013;Ctrihaloalkyl, cyano, phosphonato, and hydroxyalkyl; and Z is selected from the group consisting of substituted and unsubstituted aryl. Also provided are certain N-acylated analogs of compounds of the formula I and IX, and processes for their preparation.

Processes for the preparation of substituted isoxazoles and 2-isoxazolines

Provided is a method of treating or ameliorating a number of indications in an animal, including a human, comprising administering an effective amount of a compound of the formula I or IA,wherein J is oxygen, sulfur, or N&#x2014;R.

Method for treating fibrotic diseases or other indications utilizing thiazole, oxazole and imidazole compounds

The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula:or a pharmaceutically acceptable salt thereof.

Pharmaceutical for treatment of neurological and neuropsychiatric disorders

Provided are processes and chemical intermediates useful for preparing a compound of the formula I

Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles

Growing community of inventors

Narberth, PA, United States of America

Stanley Charles Bell